Items where authors include "Bloor, A."

Article

Duque-Afonso, J. orcid.org/0000-0002-8287-5673, Finke, J. orcid.org/0000-0002-1799-5927, Ngoya, M. et al. (21 more authors) (2024) Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 59. pp. 247-254. ISSN 0268-3369

Munir, T., Cairns, D.A. orcid.org/0000-0002-2338-0179, Bloor, A. et al. (29 more authors) (2023) Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. ISSN 0028-4793

Hillmen, P., Pitchford, A., Bloor, A. et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045

Duque-Afonso, J., Finke, J., Labopin, M. et al. (18 more authors) (2022) Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 57 (8). pp. 1269-1276. ISSN 0268-3369

Galleu, A., Milojkovic, D., Deplano, S. et al. (21 more authors) (2019) Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. British Journal of Haematology, 185 (1). pp. 89-92. ISSN 0007-1048